Compare IIIN & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IIIN | ASMB |
|---|---|---|
| Founded | 1953 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 484.9M | 442.9M |
| IPO Year | 1994 | 2010 |
| Metric | IIIN | ASMB |
|---|---|---|
| Price | $27.34 | $30.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $44.20 |
| AVG Volume (30 Days) | ★ 278.8K | 125.5K |
| Earning Date | 04-16-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.37% | N/A |
| EPS Growth | ★ 112.12 | 91.78 |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $647,706,000.00 | N/A |
| Revenue This Year | $14.20 | N/A |
| Revenue Next Year | $6.82 | $638.39 |
| P/E Ratio | $41.85 | ★ N/A |
| Revenue Growth | ★ 22.39 | N/A |
| 52 Week Low | $24.35 | $13.13 |
| 52 Week High | $41.64 | $39.71 |
| Indicator | IIIN | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 41.93 | 57.87 |
| Support Level | $24.35 | $26.50 |
| Resistance Level | $32.50 | $30.58 |
| Average True Range (ATR) | 0.94 | 1.55 |
| MACD | 0.30 | 0.36 |
| Stochastic Oscillator | 87.26 | 71.79 |
Insteel Industries Inc produces and sells prestressed concrete strand (PC strand) and welded wire reinforcement (WWR). PC strand, a high-strength seven-wire cable, is used to strengthen precast concrete in structures like bridges, parking decks, and buildings, enabling longer spans and slimmer designs. WWR includes engineered structural mesh for primary reinforcement, concrete pipe reinforcement for drainage and sewage systems, and standard WWR for crack control in residential and light commercial construction. The company serves markets in the United States and internationally, with the majority of revenue generated in the United States.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.